SP-0200: Partial nefrectomy: indication and results  by Gontero, P.
ESTRO 35 2016                                                                                                                                                    S91 
______________________________________________________________________________________________________ 
rationale for target cancer therapies based on inhibitors of 
DDR 
 
Symposium: New approaches in rectal cancer  
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Colorectal cancer (CRC) is the third most common type of 
cancer among men and the second among women in the 
European region. CRC is the second most common cause of 
cancer related death in Europe. Several trials have shown a 
mortality reduction of screening by either faecal occult blood 
test or flexible sigmoidoscopy. Next to mortality reduction, 
there also is a reduction of the CRC incidence by CRC 
screening. Furthermore, different CRC screening modalities 
have been proven to be cost-effective and maybe even cost-
saving. Most countries of the European Union do have a type 
of CRC screening, but still many countries do have 
opportunistic programs without an explicit policy, defined 
target population and without a dedicated organisation 
responsible for the roll out of the program. Preferable, CRC 
screening should be a population based program, using an up 
to date IT system/ data warehouse and with close monitoring 
and evaluation of the whole program and the outcome 
measures. Quality assurance is of utmost importance and can 
only be established in an organised program. Part of the 
results of the Netherlands CRC screening program will be 
presented as example. 
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Purpose: The delineation of clinical target volume is a 
critical step in radiation therapy procedure. Several 
contouring guidelines suggest different subvolumes and 
anatomical limits in rectal cancer, supporting a variability in 
delineation that largely depends on inter-operator 
discordance in delineation. An international agreement 
among expert radiation oncologists might significantly reduce 
this variability, converging on a consensus rectal cancer 
contouring guideline through Falcon, the educational web-
based multifunctional platform for delineation endorsed by 
ESTRO.  
 
Material and Method: Seven skilled radiation oncologists, 
delegated from ESTRO, ASTRO, TROG and EORTC, defined the 
steps to produce consensus rectal cancer guidelines on 
elective nodal levels delineation. Six rectal cancer cases with 
different clinical stage were selected and the related CT 
scans were shared and uploaded on Falcon platform. The 
experts firstly delineated online the selected CT scan slices 
following each his personal guidelines. The first delineation 
outcome was then discussed in a face-to-face meeting with 
the contribution of surgeons and radiologist and a table of 
boundaries was compiled. All the experts had then to 
delineate online the same CT scan slices, considering the new 
table of boundaries. In a peer review meeting the final 
outcome was obtained and the publication plan defined.  
 
Results: Falcon allowed a comparison of the experts’ 
delineations, identifying critical nodal boundaries as areas of 
disagreement. The ontology of structure sets was defined and 
a new table of boundaries was generated. The major 
modifications to the previously published guidelines were 
about lateral lymph nodes (LLN) and ischiorectal fossa (IRF). 
One of the discussed issues was the level of the cranial and 
anterior border of LLN according to clinical rectal cancer 
stage. The delineation of the entire IRF was recommended 
only when there was an infiltration of the external anal 
sphincter or the IRF and new limits were defined (Table). 
 
 
Conclusion: The definition of consensus guidelines for rectal 
cancer delineation endorsed by skilled radiation oncologists 
may support in reducing contouring variability. The structure 
sets of the six cases used will be available online as 
consultation atlases on the Falcon platform for individual test 
and a paper describing the agreed guidelines will be soon 
published. 
 
Symposium: Changing paradigm in the management of 
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Historically, the standard treatment modality used for the 
vast majority of small renal masses (< 4 cm) was radical 
nephrectomy (RN). Partial nephrectomy (PN) was conceived 
to preserve renal parenchyma and function. It was pioneered 
in patients who would require renal replacement after RN 
(imperative indications). Based on the “belief” that PN is 
“better” than RN, utilization of PN has increased worldwide 
in the last few years. This has been supported by extensive 
literature of retrospective studies demonstrating renal 
functional outcomes and “overall survival” benefits of PN 
over RN. For T1 renal cancer (up to 7 cm lesion according to 
current TNM), > 95% 5 years disease specific survival rates 
have been reported. The probability of a positive surgical 
margin (PSM) on the resection bed has been shown to be 
below 5%. The impact of a PSM on disease recurrence remains 
controversial with some series suggesting no additional risk 
compared to a negative margin. A tumour resection 
technique conducted at the edge of the tumour (enucleation) 
has been advocated as a mean to preserve more renal 
parenchyma and oncologically “non-inferior” to the standard 
“enucleoresection” technique where a margin of up to 1 cm 
of healthy parenchyma is left on the resected mass. Besides, 
a significant reduction in the risk of developing chronic 
kidney disease (CKD) has been reported with PN as compared 
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to RN. This has also translated into a reduced risk of all cause 
mortality in large population series receiving PN as compared 
to RN, as a result of a lower rate of cardiovascular events 
potentially driven by CKD. Backed by these data, current 
guidelines (NCCN 2015, EAU 2014 and AUA 2009) make strong 
recommendations for PN in all T1a (up to 4 cm) and 
whenever feasible in T1b (4-7 cm) kidney cancers. The 
recommendation becomes imperative in patients with 
baseline CKD, bilateral tumours or tumour in a solitary 
kidney. Surprisingly, the only level I evidence available from 
a European RCT could not prove equivalence between PN and 
RN. While the trial did not meet accrual goals (541 out of 
1300 patients required), overall survival (the primary study 
end point) at 9.3 years of follow up was eventually better in 
the RN arm in spite of a better preserved renal function in 
the PN arm. Notably more cardiovascular events were 
observed in the PN group! All these observation taken 
together suggest that the survival advantage of PN over RN 
observed in large retrospective series or metanalyses is likely 
the effect of unaccountable selection biases in favour of PN 
(healthier patients more likely to be treated with PN). The 
beneficial effect of PN on kidney function is out of question, 
yet its clinical relevancy (= reduced risk of non cancer 
related morbidity) is restricted to patients with baseline CKD. 
Up to 30% of patients with SRM have some degree of baseline 
CKD and hence would require a PN that must be performed 
with surgical skill in order to optimize both oncological 
efficacy (negative surgical margin) and kidney function 
preservation (keep ischemia time < 25 minutes or even 
lower). The currently available surgical techniques (open, 
laparoscopic and robotic assisted) have all proved effective 
to accomplish a PN matching the criteria for both oncological 
and functional efficacy.  
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Stereotactic radiotherapy for renal cell carcinoma: the 
hidden treasure or the forbidden kingdom 
G. De Meerleer
1University Hospital Ghent, Department of Radiotherapy and 
Experimental Cancer Research, Ghent, Belgium 
1 
 
Normal 0 21 false false false FR-BE X-NONE X-NONE  
Renal-cellcarcinoma (RCC) is considered to be a 
radioresistant tumour, but this dogma iswrong and based on 
traditional radiation schedules. If given in a few (evensingle) 
fractions, but at a high fraction dose (stereotactic body 
radiotherapyor SBRT), RCC becomes highly radiosensitive. 
Both in the primary setting and intreatment of 
oligometastatic disease, local control rates >90% are 
achieved.There is an established biological rationale for the 
radiosensitivity ofrenal-cell carcinoma to SBRT which is based 
on the ceramide pathway, which isactivated only when a high 
dose per fraction is given. This pathway does notinvolve 
damage at the DNA level (nucleus) but at the level of the 
cellmembrane. The ultimate target of this pathway is the 
tumour vasculature,similar to lots of targeted drugs. 
Apartfrom the direct effect of SBRT on renal-cell carcinoma, 
stereotactic bodyradiotherapy can also induce an abscopal 
effect. This effect, caused byimmunological processes and 
involving dendritic cells, might be enhanced whentargeted 
drugs and stereotactic body radiotherapy are combined. 
Therefore,rigorous, prospective randomized trials involving a 
multidisciplinaryscientific panel are needed urgently. The 
presence of a radiation oncologist insuch panels is vital. 
Thisoral presentation will focus on: 
1. Radiobiologyof SBRT in RCC (ceramide pathway). 
2. Rationalefor the abscopal effect. 
3. Localcontrol rates of SBRT in RCC. 
4. Interactionbetween targeted drugs and SBRT. 
5. Increasingvisibility if radiation oncology in this setting. 
Furtherreading 
1. DeMeerleer G, KhooV, EscudierB, et al. Radiotherapy for 
renal-cell carcinoma. Lancet Oncol 2015; 15:e170-7. 
2. De Wolf K, Vermaelen K, De Meerleer G, et al. The 
potential of radiotherapy to enhance the efficacy of renal 
cellcarcinoma radiotherapy. Oncoimmunology 2015; 4: 
e1042198. 
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There has been an increase in incidence of small renal masses 
over the last two decades. There is evidence that nephron 
sparing surgery offers equivalent long-term oncological 
results compared to radical nephrectomy. More recent 
evidence suggests that radical nephrectomy is associated 
with greater chronic renal insufficiency, which is in turn 
associated with increased risk of cardiovascular death, in 
patients with localised T1 renal mass. It is for these reasons 
that nephron sparing surgery is recommended, when 
technically feasible, for the management of renal tumour 
smaller than 7 cm.  
Partial nephrectomy is the gold standard treatment for small 
renal masses, however it is associated with a significant 
morbidity.  
Ablative treatments are alternative options that cause 
necrosis of the renal tumour without removing it. This can be 
achieved by heating tumour up to 80°C, with radiofrequency, 
or by freezing it below -40°C with cryosurgery. These 
percutaneous ablative treatments are performed under CT 
scan guidance or by laparoscopic approach. The percutaneous 
approach can be performed under local anaesthesia, which is 
particularly useful in fragile patients. These two minimally 
invasive ablative treatments allow, on average, to halve the 
postoperative morbidity when compared to partial 
nephrectomy. On the other hand, the risk of local recurrence 
is higher compared to partial nephrectomy. 
Cancer specific survival rate on literature review is quoted 
around 90 to 95% for T1a (<4 cm) tumours. The 5 years 
overall survival or metastatic free survival, don’t seem to be 
different from partial nephrectomy, if salvage treatments are 
proposed in case of local recurrence. To achieve these 
oncological results, appropriate patient selection along with 
adequate follow up is required.  
According to the various urological guidelines, renal biopsy 
must be performed prior to these ablative treatments. When 
a malignant tumour is confirmed histologically, these 
treatments are recommended for cortical tumours, smaller 
than 4 cm, ideally in elderly patients or patients with 
multiple comorbidities who have a reasonable life 
expectancy. Patients with bilateral synchronous tumours, 
genetic diseases leading to multiple bilateral recurrences, 
renal insufficiency or presence of solitary kidney, are also 
ideal candidates for ablative treatments. Patients with 
shorter life expectancy, tumours in the hilum or in close 
proximity to the collecting system and proximal ureter are 
contraindications. Cryosurgery appears to treat central 
tumours with less morbidity compared to radiofrequency 
ablation. Close radiological follow up is required. Renal CT 
scan or MRI is usually performed at regular intervals looking 
for any possible enhancement of recurrent/residual tumour.  
Conclusion: Partial nephrectomy remains the gold standard 
treatment for management of small renal tumours. Ablative 
treatment is a validated option associated with a favourable 
risk benefit balance, especially for fragile patients.  
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The practice of brachytherapy nowadays has been developed 
decennia ago. In the course of years modifications are 
introduced by the use of different isotopes, the development 
of afterloading techniques, the introduction of image-guided 
techniques, and many more. Robotics technologies are on a 
wide scale increasingly being used in the treatment of 
patients. Also in brachytherapy this emerging technology has 
been adopted and is still in development. A robot is a 
